Initial Approval: July 10, 2013

CRITERIA FOR PRIOR AUTHORIZATION

Tofacitinib

PROVIDER GROUP Pharmacy

Professional

MANUAL GUIDELINES The following drug requires prior authorization:

Tofacitinib (Xeljanz®)

CRITERIA FOR RHEUMATOID ARTHRITIS (RA) Must meet all of the following:

- Patient must have a diagnosis of moderate to severe, active rheumatoid arthritis
- Patient must have had an inadequate response or intolerance to methotrexate
- Must be prescribed by or in consultation with a rheumatologist
- Patient must have an evaluation for latent tuberculosis (TB) with a TB skin test prior to initial prior authorization approval
- Patient must be 18 years of age or older
- Patient has not taken a biologic agent (see attached table) in the past 30 days
- Patient must have had the following labs checked prior to initial prior authorization
 - lymphocyte count
 - o absolute neutrophil count (ANC)
 - o hemoglobin

RENEWAL CRITERIA FOR RA Must meet all of the following:

- Patient must have the following labs checked every 3 months
 - lymphocyte count
 - o ANC
 - o hemoglobin

LENGTH OF INITIAL AND RENEWAL APPROVAL

6 months

Biologic Agents	
Generic Name	Brand Name
Abatacept	Orencia®
Adalimumab	Humira®
Alefacept	Amevive®
Anakinra	Kineret®
Certolizumab	Cimzia®
Golimumab	Simponi [®]
Infliximab	Remicade®
Natalizumab	Tysabri®
Rituximab	Rituxan®
Tocilizumab	Actemra®
Tofacitinib	Xeljanz [®]
Ustekinumab	Stelara®